Research programme: meningococcal vaccine group B - Aventis-Pasteur

Drug Profile

Research programme: meningococcal vaccine group B - Aventis-Pasteur

Alternative Names: Meningococcal group B vaccine; Meningococcal-vaccine-group-B-Emergent-BioSolutons

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Meningococcal group B infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Meningococcal-group-B-infections in France (Parenteral, Injection)
  • 17 Mar 2009 Preclinical development is ongoing with Sanofi Pasteur
  • 05 Jun 2006 Preclinical trials in Meningococcal group B infections in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top